Background A high incidence rate of hepatitis B or C virus infection is found among thalassemia children in Indonesia. This may influence deferiprone effectiveness. Objective To determine the effectiveness of deferiprone in thalassemia children with or without hepatitis B or C virus infection. Methods A non-randomized clinical study was performed at
T halassemia is one of the most common genetic disorders in the world with estipopulation. patients registered at Thalassemia Center Cipto patients each year. 2 Thalassemia is a disorder where one or more globin chain production is reduced. This ineffective erythropoiesis results in mild to severe degree of anemia. Packed red cell transfusion is still the mainstay management to ensure child's optimal growth and development. Iron overload is an inevitable consequence of regular transfusion, which leads to organ dysfunction. Iron chelation therapy has been widely known to increase survival. Deferoxamine (DFO) is the conventional parenteral iron chelating agent. However, low compliance rate is found with DFO therapy due to its relatively difficult administration. The first oral iron chelating agent, deferiprone, has been proven to have comparable effectiveness and safety with DFO and has been claimed to be superior to DFO in reducing cardiac iron overload.
Thalassemia patients in Indonesia face another problem of high incidence of transfusion-associated hepatitis B or C virus infection rate. In 2008, there were with hepatitis C. 2 This chronic infection is suggested to influence the effectiveness of iron chelation therapy. On personal observation in Thalassemia Center Jakarta, thalassemia patients with chronic infection, particularly hepatitis B or C virus infection, do not have serum ferritin level reduction as good as those without infection, while receiving similar adequate iron chelation therapy. Studies on deferiprone effectiveness in thalassemia patients in Indonesia and the effect of hepatitis virus infection status on the therapy are still limited. This study aimed to determine the effectiveness of deferiprone in reducing iron overload in thalassemia hepatitis B or C virus infection.
Methods
A non-randomized clinical trial was performed in including thalassemia-homozygote and thalassemia /HbE patients with severe clinical manifestations) recruited consecutively with serum feritin level virus infection (determined by positive anti-HCV, HbsAg, or total anti HBc). The exclusion criteria consist of renal impairment, liver failure, heart failure, pregnant and lactating woman. A match control pair was recruited purposively based on similar duration of transfusion therapy, thalassemia received initial deferiprone dose of 50 mg/kg/day continued to receive deferiprone of 50 mg/kg/day for the following 3 months. Otherwise, deferiprone three months, complete laboratory evaluation was perfomed. Data was analyzed using SPSS for windows P significant. Ethical clearance was obtained from Ethical Committee Faculty of Medicine University of Indonesia.
Results
virus infection (Figure 1) . of hepatitis B virus infection (positive total antitransfusion volume (ml/kg) during study period in both groups was similar. Mean serum ferritin levels, mean pre-transfusion hemoglobin levels, as well as other supporting examinations parameter in both groups were comparable ( Table 1) .
rate was similar between both groups (82.5 (SD 9.3) or C virus infection respectively).
Treatment with deferiprone of 50 mg/kg/day for the first three months resulted in reduced mean deferiprone dose continued to be given on dose of evaluation after the second three months of therapy decrement ( Table 2) . Mean decrement of serum ferritin level was both hepatitis B and C virus infection had her Table 3 shows decrement percentage of mean serum ferritin level in the control group is higher than in the group with hepatitis B or C virus infection (P group with hepatitis B or C virus infection needed larger mean deferiprone dose than control group (P=0.020).
When further classified based on hepatitis with hepatitis C virus infection was higher than those with hepatitis B infection and than control (Table 4) .
kg/day resulted in adverse events of included nausea, vomiting, leukopenia, neutropenia, and and vomiting were generally found only in the who continued to experience them through the third month. Leukopenia and neutropenia could be found at anytime during study period.
without hepatitis B or C virus infection on the last laboratory examination. There was no arthropathy was reported. The numbers of adverse events between two groups are comparable ( Table  5 ).
Discussion
The limitation of this study is that iron overload status and therapy effectiveness were assessed only by serum ferritin level examination. Although it is the most widely used parameter, ferritin value may be affected by acute conditions such as fever and infection. Another limitation is that compliance rate was obtained by history taking only in which inaccurate information might be given. This study shows that initial serum ferritin level poor chelating in the past. Serum ferritin level >2500 ng/mL is related to increased risk of cardiomyopathy.
function based on echocardiography. However, Anderson et al reported that echocardiography is not sensitive enough to detect early heart dysfunction due to iron overload. Ideally, every thalassemia patient evaluate cardiac iron overload, but unfortunately, this test is not available in our center yet. Compliance rate in this study was good in both 8 reported similar compliance rate of 85±3%, while Cohen et al 9 reported a higher rate of 93±8%. Previous iron chelation therapy with deferoxamine compliance rate in Thalassemia Center Jakarta was reported to be very 2 This may be due to difficulty in DFO administration and drug availability.
In this study, deferiprone therapy of 50 mg/ WBC= white blood cells, ANC = absolute neutrophil count, UNL = upper normal limit (1506) 20 (20) 66 (13) 4950 (2509) 4717 (2325) 2 (22) 72 (9) 4744 (2091) 3452 (1550) 27 (11) 58 (12) years). Addis et al in their meta-analysis defined had serum ferritin level reduction. Negative iron balance based on urine iron excretion measurement Deferiprone dose of 50 mg/kg/day,used in this study, was the minimal initial dose suggested. This dose was applied in Thalassemia Center Jakarta because many patients came from underprivileged families. This study shows that this dose is effective
The difference of this study with previous studies other studies included adults. Besides, thalassemia-/ were also recruited, whereas other studies had more homozygote. Pootrakul et al in their study of thalassemia-/HbE found that low dose of deferiprone (25-50 mg/kg/day) was effective in reducing iron overload. deferiprone therapy was significantly higher in group with hepatitis B or C virus infection (P = 0.032) than in group without hepatitis B or C virus infection. In this study, subgroup analysis based on hepatitis hepatitis C virus infection (n=8) required larger hepatitis B infection and than control. Percentage of serum ferritin decrement between three groups were also different. Until currently, there is no particular study that can explain this phenomenon. Increased liver iron due to hepatitis C virus might be the reason why it is difficult to achieve negative iron balance although iron chelation has been administered in virus might need larger iron chelation dose. Adverse events of deferiprone therapy occurred in this study was similar to those reported in previous studies. Nausea and vomiting were the most common et al 9 symptoms are usually resolved in the first week of experience nausea through the third month.
Neutropenia was reported in 5% patients receiving deferiprone, and was idiosyncratic and unpredictable in nature. 9 In this study, leucopenia (white blood cells happen 0.5% pasien, was not found in this study.
ALT >2x upper normal limit. Liver enzyme elevation is a common finding in deferiprone therapy, with incidence rate around 20%, occurs predominantly and generally does not require therapy modification. Renal and heart function evaluation after study were between normal limits, comparable to previous studies where no renal or heart toxicity was found. 9 in other studies, namely arthropathy, was not found in this study. Risk factors to arthropaty include high dose of deferiprone, and high degree of body iron overload. The low initial dose of deferiprone (50 mg/kg/day) used in this study may explain why no arthropathy was reported.
Adverse events rate between two groups were comparable. This is similar to study by Chen et al who did not found significant difference in adverse events infection. Increased serum ALT serum occurred in Risk factor that increased serum ALT was hepatitis virus infection. 9 hepatitis B or C virus infection than in those with hepatitis B or C virus infection, where lower dose is required, lower mean serum ferritin level after therapy and higher mean decrement percentage are obtained. There was no fatal adverse event found in this study. Number of adverse events between two groups are comparable.
Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia. Hemoglobin.
